← Back to Clinical Trials
Recruiting Phase 4 NCT05758701

CT TAVR Abdomen Study

Trial Parameters

Condition Transcatheter Aortic Valve Replacement
Sponsor University of Maryland, Baltimore
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 164
Sex ALL
Min Age 18 Years
Max Age 88 Years
Start Date 2023-09-19
Completion 2027-03-01
Interventions
Iodinated Contrast Agent (Omnipaque)Dual Energy CT

Brief Summary

A standard polyenergetic CT (computed tomography) procedure utilizes 100 ml of iodinated contrast. A recent world-wide shortage of iodine based intravenous contrast has highlighted the need to search for alternative methods or doses. Reducing iodinated IV contrast dose can mitigate IV contrast supply shortages and enable significant cost savings for the radiology practice and hospital system. In addition, decreased IV contrast dose can potentially reduce the rate of acute kidney injury, specifically in patients with decreased renal function. The purpose of the study is to determine whether low IV contrast dose CT with monoenergetic reconstruction can be use for presurgical planning of transcatheter valve replacement (TAVR) procedure.

Eligibility Criteria

Inclusion Criteria: * scheduled to receive TAVR abdominal CT Exclusion Criteria: * cannot undergo CT scan * Allergy to intravenous contrast not controlled by steroids or benadryl * GFR\<30

Related Trials